Evaluation of a Digital Microscope for Malaria

Malaria Clinical Trial

— EasyScanGo  

Official title:

A Multi-Centric Evaluation of a Device for Automated Malaria Microscopy (EasyScan Go)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03512678
• Other study ID #: MAL18002
• Status: Completed
• Start date: June 25, 2018
• Est. completion date: June 30, 2020

Study information

• Verified date: September 2020
• Source: University of Oxford
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Light microscopy, which is based on century-old technology, remains a key indicator in drug efficacy testing performed in the context of clinical trials for monitoring existing antimalarial drugs or in the context of regulatory clinical trials for registration of new drugs. It is one of the main diagnostic methods for malaria diagnosis in general, as in an ideal setting it can provide low-cost accurate diagnosis, determine the density of parasites in the blood, and accurately differentiate between different malaria parasite species, characteristics vital to the implementation of global plans for drug efficacy monitoring. Malaria rapid tests (RDTs), while useful for rapid diagnosis and case management, do not provide information on the parasite density nor the species differentiation necessary for research and drug efficacy assessment. Microscopy therefore retains key advantages over a number of newer technologies, but its reliability is severely impeded by dependence on high technical competence of the human operators as well as availability of high quality equipment and reagents. Recent studies have demonstrated frequent poor specificity and sensitivity associated with manual microscopy diagnostics in operational conditions. These drawbacks constitute a major limiting factor to effective monitoring and preservation of vital anti-malarial medicines.

Advances in digital microscopy performance and affordability have now opened the door to potentially significant improvements in the performance of malaria microscopy, overcoming serious deficiencies in current drug efficacy assessment, and more broadly in malaria diagnosis and management. Global Good (GG)/Intellectual Ventures Laboratory (IVL) sponsored by the Global Good Fund, has developed a microscope prototype consisting of low cost components to scan and capture images from Giemsa-stained thick blood films on slides. The captured images are analyzed with custom image analysis software developed at GG/IVL, using algorithms that are designed for automatic malaria diagnosis, without user input. Versions of a prototype of the device were first tested in field settings in Thailand in 2014-2015 at clinics operated by the Shoklo Malaria Research Unit (SMRU) and then again in 2016-2017. When compared to expert microscopy at SMRU, the performance of the device with respect to diagnostic sensitivity (87.8%), species identification (85.6% species correctly identified) and parasite density estimation (44% of estimates within +/-25% of reference microscopy result) corresponded to WHO Competence Level 2. The device and the accompanying image analysis algorithms have since been further developed and a new, third version of the prototype is now available for testing in diverse settings with varying malaria prevalence and user expertise.

Description:

The primary purpose of this evaluation is to quantify the diagnostic performance of the EasyScan Go prototype in various field settings. The performance of the EasyScan Go prototype will be assessed by scanning of negative and positive slides with the EasyScan Go and comparing the results with expert microscopy. Plasmodium genus- and species-specific PCR will also be performed on samples collected at some sites as an additional confirmatory test for the detection of malaria parasites and their species if present. Testing by microscopy and EasyScan Go will be performed in field clinic settings on Giemsa-stained slides prepared from febrile patient blood collected from a finger-prick. Further work will be undertaken at the WWARN laboratory in Bangkok for data analyses and for quality assurance.

Funder: Intellectual Ventures Lab/Global Good (2018) Sponser: University of Oxford Grant refernce number:The Global Good Fund I, LLC PA No.5

Recruitment information / eligibility

• Status: Completed
• Enrollment: 2250
• Est. completion date: June 30, 2020
• Est. primary completion date: October 31, 2019
• Gender: All
• Age group: 6 Months to 75 Years

Eligibility

Inclusion Criteria:

• Male or female subjects, age = 6 months to 75 years

• Febrile at presentation or history of fever in the past 48 hours (= 37.5 ºC) and no other obvious diagnosis or cause for fever, warranting malaria investigation under routine clinical practice.

• Individual informed assent/consent obtained

Exclusion Criteria:

• Signs of severe malaria as defined by WHO

Related Conditions & MeSH terms

• Malaria

Locations

Country	Name	City	State
Thailand	Shoklo Malaria Research Unit	Mae Sot	Tak

Sponsors (1)

Lead Sponsor	Collaborator
University of Oxford

Country where clinical trial is conducted

Thailand, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Diagnostic sensitivity for malaria parasite detection		6 months
Primary	Diagnostic specificity for malaria parasite detection		6 months
Primary	Kappa statistic for parasite species identification		6 months
Primary	Bland-Altman plots for parasite density estimation		6 months
Secondary	Reliability (comparison between 2 devices and repeat reads)		6 months
Secondary	Cost-effectiveness as compared with routine methods		6 months
Secondary	Prevalence of parasite genetic markers of resistance to antimalarials by location and time period		6 months
Secondary	Prevalence of parasites carrying deletions of pfhrp2/3 genes by location and time period		6 months